Skip to content
Select your cancer type
▼
  • ESCC
  • GC/GEJC
  • NSCLC
Indication:
▼
  • 1 L ESCC
  • 1 L GC/GEJC
  • 2 L ESCC
  • Non-Squamous NSCLC
  • Squamous NSCLC

Language

This site is inteded for health care proffesional.

Improved ORR, mDoR, and mPFS in patients with 1L ESCC and PD-L1 scores ≥1%1

Additional Efficacy Outcomes: ORR, mDoR, and mPFS in PD-L1 ≥1%

Limitation: Secondary endpoints were not powered for statistical comparison and are descriptive only. No definitive conclusions can be drawn.
View safety in 1L ESCC

1L, first line, ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; mDoR, median duration of response; mPFS, median progression-free survival; ORR, overall response rate; OS, overall survival; PD-L1, programmed death ligand 1.

Reference: 1. etapidi. Prescribing Information. BeOne Medicines USA, Inc.